Clinical trials
Advanced Lung Cancer clinical trials
Below are recruiting advanced lung cancer clinical trials, each written for real people, not researchers. We’re tracking 1,300 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT06955988RecruitingPhase 1
Safety and early results of AST2303 for advanced lung cancer
This trial tests a new oral drug, AST2303 (ABK3376), in people with advanced non-small cell lung cancer that has not responded to other treatments. It aims to see if the drug is safe and whether it can shrink tumors.
Shanghai, Shanghai MunicipalityAges 18 years+ - NCT06311981RecruitingPhase 2
Carbon ion radiation for elderly lung cancer patients
This trial tests carbon ion radiotherapy for adults 75 and older with locally advanced non-small cell lung cancer who cannot have surgery. The goal is to see if this precise type of radiation can treat the cancer effectively with fewer side effects.
Shanghai, Shanghai MunicipalityAges 75 years+ - NCT06205927RecruitingPhase 2
Carbon Ion Boost for Advanced Lung Cancer
This trial tests a new way to give radiation therapy (carbon ion boost) to people with advanced, inoperable lung cancer. The goal is to see if targeting the most aggressive parts of the tumor with a higher dose can improve outcomes.
Shanghai, Shanghai MunicipalityAges 18–80 - NCT06775678RecruitingPhase 2
Spatial fragmentation plus low-dose radiation for resistant lung cancer
This study tests whether combining a special type of radiation (spatial fragmentation) with low-dose radiation can help people whose lung cancer stopped responding to immunotherapy and chemotherapy. If you are eligible, you may receive a new treatment approach to try to shrink the tumors.
Tianjin, Tianjin MunicipalityAges 18 years+ - NCT06928922RecruitingEarly Phase 1
Inhaled mRNA vaccine for advanced lung cancer and lung metastases
This trial tests an inhaled dry powder vaccine that uses mRNA to help your immune system target cancer cells in the lungs. It is for people with advanced lung cancer or solid tumors that have spread to the lungs, who have already tried standard treatments.
BeijingAges Up to 99 years - NCT06926140Recruiting
Acupuncture with immunotherapy for advanced lung cancer
This trial tests if adding acupuncture to standard immunotherapy and chemotherapy helps people with advanced lung cancer. It is for those who have not had treatment before and whose tumors have low PD-L1 levels.
Hefei, AnhuiAges 18–75 - NCT06928389RecruitingPhase 3
Ivonescimab plus docetaxel for advanced lung cancer
This trial tests a new drug called ivonescimab combined with a chemotherapy drug (docetaxel) for advanced non-small cell lung cancer. It's for people who have already tried platinum-based chemo and a PD-1/PD-L1 inhibitor, and who have not had docetaxel before.
Shanghai, Shanghai MunicipalityAges 18–75 - NCT06917079RecruitingPhase 1
BBO-11818 for KRAS-mutated cancers
This trial tests a new oral drug (BBO-11818) for people with solid tumors that have a specific KRAS mutation. It's for those whose cancer has spread or cannot be removed by surgery and who have not had other cancers recently.
Los Angeles, CaliforniaAges 18 years+ - NCT06918132RecruitingPhase 2
Cemiplimab and Fianlimab before lung cancer surgery
This trial tests whether two immunotherapy drugs (cemiplimab and fianlimab) given before surgery can help treat stage IB to IIIB non-small cell lung cancer. You must have a PD-L1 level of at least 1% and your surgeon must think the tumor can be fully removed.
Rochester, MinnesotaAges 18 years+ - NCT06769425RecruitingPhase 1
Combination treatment for advanced solid tumors
This trial tests a new combination treatment for people with advanced solid tumors that have not responded to standard therapy. It aims to find a safe dose and see if the combination can shrink tumors.
Shanghai, Shanghai MunicipalityAges 18 years+ - NCT06910657RecruitingPhase 1
IDOV-Immune vaccine for advanced solid tumors
This trial tests an experimental virus-based treatment for people with advanced solid tumors that have stopped responding to standard therapies. The treatment is designed to infect and destroy cancer cells while boosting the immune system.
St Louis, MissouriAges 18 years+ - NCT06903377RecruitingPhase 1/Phase 2
ZG005 plus Gecacitinib for advanced lung cancer
This trial tests a new combination of two drugs, ZG005 and Gecacitinib, for people with advanced non-small cell lung cancer that cannot be treated with surgery or radiation. The goal is to see if the combination can shrink or slow the cancer.
Shanghai, Shanghai MunicipalityAges 18–75 - NCT06907615RecruitingPhase 2
Study of HLX43 for advanced non-small cell lung cancer
This trial tests a new drug, HLX43, for people with advanced non-small cell lung cancer that has not responded to standard treatments. It aims to see if HLX43 can help shrink or control the cancer.
Houston, TexasAges 18 years+ - NCT06908993RecruitingPhase 3
Tepotinib vs standard care for MET-mutated lung cancer
This trial tests a targeted pill called tepotinib against standard treatments for advanced lung cancer with a specific MET gene change. It is for people whose cancer has progressed after at least one prior therapy.
BesançonAges 18 years+ - NCT03175224RecruitingPhase 2
Test drug APL-101 for lung or other tumors with MET changes
This Phase 2 study tests APL-101 to shrink advanced cancers that have certain MET-related changes, including specific MET mutations, MET gene amplification, or MET fusions. It may help people whose tumors have run out of standard treatment options.
Los Angeles, CaliforniaAges 18 years+ - NCT06892548RecruitingPhase 1/Phase 2
Combination therapy for advanced lung cancer
This trial tests a new combination of two investigational drugs, BNT324 and BNT327, for people with advanced lung cancer that cannot be removed by surgery. It aims to see if the combination is safe and effective for different types of lung cancer, including non-small cell and small cell lung cancer.
Phoenix, ArizonaAges 18 years+ - NCT06881784RecruitingPhase 3
Study of a RAS-targeting pill for lung cancer
This trial tests a new daily pill (daraxonrasib/RMC-6236) for people with advanced non-small cell lung cancer that has a specific RAS mutation. It's for those who have already tried 1 or 2 previous treatments, including immunotherapy and chemotherapy.
Birmingham, AlabamaAges 18 years+ - NCT03093688RecruitingPhase 1/Phase 2
Testing an immune-cell infusion for advanced solid tumors
This trial tests whether adding special immune cells (iNKT cells and CD8+ T cells) given by IV infusion can help treat advanced cancers. It mainly looks at safety first, and also checks whether the treatment can shrink or control cancer.
Shanghai, Shanghai MunicipalityAges 18–70 - NCT06868485RecruitingPhase 2
Study of WSD0922-FU for advanced lung cancer with C797S mutation
This trial tests a new drug, WSD0922-FU, for people with advanced non-small cell lung cancer that has a specific genetic change called C797S. It is for those whose cancer has gotten worse after treatment with osimertinib.
Oxnard, CaliforniaAges 18 years+ - NCT06861543RecruitingPhase 1
TMT101 for advanced pancreatic or lung cancer
This trial tests a new drug called TMT101 for people with advanced pancreatic cancer or non-small cell lung cancer who have already tried other treatments. The goal is to see if TMT101 is safe and works against the cancer.
Beijing, Beijing MunicipalityAges 18 years+ - NCT06773507RecruitingPhase 1
Study of BC008-1A for advanced solid tumors
This trial tests a new drug called BC008-1A for people with advanced esophageal cancer or non-small cell lung cancer that has not responded to standard treatments. The goal is to see if the drug is safe and effective.
TianjinAges 18 years+ - NCT06835569RecruitingPhase 1
ALTA3263 for advanced KRAS-mutated solid tumors
This trial tests an experimental pill called ALTA3263 for adults with advanced solid tumors that have a specific KRAS mutation. It's for people who have already tried other treatments or can't take them.
Orlando, FloridaAges 18 years+ - NCT06822543RecruitingPhase 2
A new treatment for lung cancer that has spread to the brain
This trial tests a combination of three drugs (datopotamab deruxtecan, carboplatin, and pembrolizumab) for people with a type of lung cancer called non-small cell lung cancer (NSCLC) that has spread to the brain and has not been treated before. The goal is to see if this combination can shrink tumors in the brain and elsewhere.
Fortaleza, CearáAges 18 years+ - NCT06167460Recruiting
Blood test to monitor targeted therapy response in advanced lung cancer
This study uses a simple blood test to look at bits of tumor DNA (called circulating tumor DNA) to see how well your targeted therapy (TKI) is working. It helps doctors predict and monitor whether the treatment is effective for your advanced lung cancer.
Ho Chi Minh CityAges 18–80
Hear when a new Advanced Lung Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for advanced lung cancer?
- Yes. Clin2 currently lists 1,300 recruiting advanced lung cancer studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a advanced lung cancer trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a advanced lung cancer trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
- NSCLC (Advanced Non-small Cell Lung Cancer)
- Non Small Cell Lung Cancer
- Locally Advanced Non-Small Cell Lung Cancer
- Locally Advanced or Metastatic Non-small Cell Lung Cancer
- Advanced or Metastatic Non-small Cell Lung Cancer
- Lung Cancer (Locally Advanced or Metastatic)
- Lung Cancer Non-Small Cell Cancer (NSCLC)
- EGFR Mutant Advanced Non-small Cell Lung Cancer
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.